|Sample Type||HTG EdgeSeq Precision Immuno-Oncology Panel|
Larger sample input amounts must be diluted. Please consult the assay package insert and HTG EdgeSeq System User Manual for more details.
|FFPE Tissue||One 5 µm section|
|Extracted RNA||10 - 35 ng|
The breadth of the immune response in a tumor can be measured using the HTG EdgeSeq Precision Immuno-Oncology Panel. Relatively higher levels of IFNG (interferon γ), a key pro-inflammation cytokine, are measured in non-small cell lung cancer samples 3 and 5. IFNG production stimulates the production of T-cell attractant chemokines CXCL9, CXCL10, and CCL5, with a subsequent increase in production of cytolytic molecules such as perforin and granzymes.
Immune loads of NSCLC tumors were assessed using T cell (CD3, CD4, and CD8) markers as well as CD68 (macrophages, myeloid cells). A range of expression was obtained indicating variable loads of immune cells.
Genes associated with WNT (WNT5A) and EMT drivers (ZEB1, TWIST1) are more highly expressed in tumors with lower immune loads. NK cells (NCAM1) are seen at higher levels in tumors with WNT and/or EMT activity, consistent with the literature report.
HTG EdgeSeq Reveal is a powerful software product that streamlines analysis of biomarker data from samples analyzed with the
HTG EdgeSeq Precision Immuno-Oncology Panel on the HTG EdgeSeq system. HTG EdgeSeq Reveal enables characterization and visualization of immune response in the tumor environment which continues to be an important step in developing biomarker strategies to understand the body’s immune response in relation to cancer biology and potential response to mono- and combination therapies. The HTG EdgeSeq Reveal was designed to be a scalable, flexible data analysis product that will expand with new applications to support HTG’s growing translational research product portfolio.
HTG’s new product, when coupled with the HTG EdgeSeq Precision Immuno-Oncology Panel, enables applications such as:
Together with the HTG EdgeSeq system, customers using the new HTG EdgeSeq Reveal product will have the ability to conduct molecular profiling using a wide variety of sample types, potentially enabling them to accelerate discovery, support translational applications, and determine potential biomarkers for development of companion diagnostics.
For more information and a product demonstration, contact your HTG representative.
When placing an order, please specify the catalog number. The HTG EdgeSeq Precision Immuno-Oncology Panel is compatible with Illumina sequencers .
916-011-208 HTG EdgeSeq Precision I/O Panel (2 X 8)
916-011-008 HTG EdgeSeq Precision I/O Panel (4 X 8)
916-011-224 HTG EdgeSeq Precision I/O Panel (1 X 24)
916-011-024 HTG EdgeSeq Precision I/O Panel (4 X 24)
916-011-096 HTG EdgeSeq Precision I/O Panel (1 X 96)
Learn more about the HTG EdgeSeq Precision Immuno-Oncology Panel
Annotated Gene List HTG EdgeSeq Precision Immuno-Oncology Panel
Download pdf 128KB
HTG EdgeSeq Precision Immuno-Oncology Panel Gene List
Download pdf 148KB
HTG EdgeSeq Precision Immuno-Oncology Panel Product Sheet
Download pdf 354KB
Tech Note: Assessing Tumor Inflammation
Download pdf 61KB
Tech Note: Epithelial Mesenchymal Transition in Immuno-Oncology
Download pdf 62KB
Tech Note: Immunophenotyping Lymphocytes in Tumors
Download pdf 62KB
Tech Note: Measuring Immune Checkpoint Genes from FFPE Tissue
Download pdf 53KB
The Advantages of HTG EdgeSeq System & Chemistry
Download pdf 230KB
Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment - Implication for Therapeutic Benefit in the Immunotherapy Era
Download pptx 4.4MB
Next Generation Sequencing and Functional Pathway Analysis to Understand the Mechanism of Action of Copper-Tolfenamic Acid Against Pancreatic Cancer.
View External Link
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
Download pdf 16.7MB
Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.
Download pdf 1.3MB
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial
Download pdf 1.0MB
Dynamic change of immune-related gene expression status during chemoradiotherapy in locally advanced esophageal cancer
View External Link
For further information about the HTG EdgeSeq Precision Immuno-Oncology Panel, please fill out the registration form below or call us at (877) 507-3259.
Page last updated March 10, 2020